GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » Cyclically Adjusted FCF per Share

PTGX (Protagonist Therapeutics) Cyclically Adjusted FCF per Share : $-1.53 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Protagonist Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2025 was $1.982. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.53 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-07-09), Protagonist Therapeutics's current stock price is $52.29. Protagonist Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was $-1.53. Protagonist Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Protagonist Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Protagonist Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagonist Therapeutics Cyclically Adjusted FCF per Share Chart

Protagonist Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -1.76

Protagonist Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -1.76 -1.76 -1.53

Competitive Comparison of Protagonist Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Protagonist Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagonist Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Protagonist Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Protagonist Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protagonist Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.982/134.9266*134.9266
=1.982

Current CPI (Mar. 2025) = 134.9266.

Protagonist Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.596 100.684 -0.799
201509 -0.660 100.392 -0.887
201512 -0.843 99.792 -1.140
201603 -0.933 100.470 -1.253
201606 -0.496 101.688 -0.658
201609 -0.825 101.861 -1.093
201612 -0.582 101.863 -0.771
201703 -0.621 102.862 -0.815
201706 -0.752 103.349 -0.982
201709 2.396 104.136 3.104
201712 -0.702 104.011 -0.911
201803 -0.727 105.290 -0.932
201806 -0.729 106.317 -0.925
201809 -0.411 106.507 -0.521
201812 -0.421 105.998 -0.536
201903 -0.693 107.251 -0.872
201906 0.113 108.070 0.141
201909 -0.517 108.329 -0.644
201912 -0.525 108.420 -0.653
202003 -0.577 108.902 -0.715
202006 -0.659 108.767 -0.817
202009 -0.438 109.815 -0.538
202012 -0.479 109.897 -0.588
202103 -0.653 111.754 -0.788
202106 -0.539 114.631 -0.634
202109 -0.599 115.734 -0.698
202112 -0.563 117.630 -0.646
202203 -0.778 121.301 -0.865
202206 -0.284 125.017 -0.307
202209 -0.516 125.227 -0.556
202212 -0.644 125.222 -0.694
202303 -0.679 127.348 -0.719
202306 -0.465 128.729 -0.487
202309 -0.456 129.860 -0.474
202312 0.280 129.419 0.292
202403 -0.435 131.776 -0.445
202406 4.381 132.554 4.459
202409 -0.464 133.029 -0.471
202412 -0.444 133.157 -0.450
202503 1.982 134.927 1.982

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Protagonist Therapeutics  (NAS:PTGX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Protagonist Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Protagonist Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagonist Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Executives
Asif Ali officer: Chief Financial Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Patel Dinesh V Ph D director, officer: President and CEO C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Suneel Gupta officer: Chief Development Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd director 3185 LAURELVIEW COURT, FREMONT CA 94538
Harold E Selick director
Bryan Giraudo director 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Donald A. Kalkofen officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu officer: Chief Scientific Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame officer: Chief Medical Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035

Protagonist Therapeutics Headlines

From GuruFocus